April 22, 2019
Sumitomo Dainippon Pharma said on April 19 that it has amended its earnings outlook for FY2018 ended March 2019, shedding its sales forecast due to stagnant revenues from its antipsychotic Latuda (lurasidone) in the North America. In a revised outlook,...read more